Cargando…
A novel series of phenolic temozolomide (TMZ) esters with 4 to 5-fold increased potency, compared to TMZ, against glioma cells irrespective of MGMT expression
The standard of care treatment for patients diagnosed with glioblastoma multiforme (GBM) is temozolomide (TMZ). Tumour resistance to TMZ results in significantly limited clinical effectiveness. There is therefore an inherent need for alternatives to TMZ capable of overcoming resistance associated wi...
Autores principales: | Shervington, Leroy, Ingham, Oliver, Shervington, Amal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Royal Society of Chemistry
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9053583/ https://www.ncbi.nlm.nih.gov/pubmed/35515578 http://dx.doi.org/10.1039/d0ra02686g |
Ejemplares similares
-
Investigating the Stability of Six Phenolic TMZ Ester Analogues, Incubated in the Presence of Porcine Liver Esterase and Monitored by HPLC
por: Shervington, Leroy A., et al.
Publicado: (2022) -
Could the Anti-Chaperone VER155008 Replace Temozolomide for Glioma Treatment
por: Shervington, Leroy, et al.
Publicado: (2015) -
Experimental study of selective MGMT peptides mimicking TMZ drug resistance in glioma
por: Wu, Yue, et al.
Publicado: (2022) -
TMZ-BioShuttle – a reformulated Temozolomide
por: Waldeck, Waldemar, et al.
Publicado: (2008) -
OKN-007 Increases temozolomide (TMZ) Sensitivity and Suppresses TMZ-Resistant Glioblastoma (GBM) Tumor Growth()()
por: Towner, Rheal A., et al.
Publicado: (2018)